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Aneuploidy—the gain or loss of one or more whole chro-
mosome—typically has an adverse impact on organismal
fitness,manifest in conditions such as Down syndrome. A
central question is whether aneuploid phenotypes are the
consequence of copy number changes of a few especially
harmful genes that may be present on the extra chromo-
some or are caused by copy number alterations of many
genes that confer no observable phenotype when varied
individually. We used the proliferation defect exhibited
by budding yeast strains carrying single additional chro-
mosomes (disomes) to distinguish between the “few crit-
ical genes” hypothesis and the “mass action of genes”
hypothesis. Our results indicate that subtle changes in
gene dosage across a chromosome can have significant
phenotypic consequences. We conclude that phenotypic
thresholds can be crossed by mass action of copy number
changes that, on their own, are benign.
Supplemental material is available for this article.
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The impact of whole-chromosome gains and losses on hu-
man health is severe. Aneuploidy is the leading cause of
miscarriages and mental retardation (Hassold and Jacobs
1984). It is also a hallmark of solid tumors: Seventy-five
percent to 90% of tumors harbor abnormal karyotypes
(Weaver and Cleveland 2006). Despite aneuploidy’s dra-
matic impact on health, we are only beginning to under-
stand how it affects cells and organisms.
Identifying the source of phenotypes observed when
chromosome copy number is changed is central to under-
standing how aneuploidy affects cellular and organismal
fitness. Changes in copy number (and thus expression lev-
el) of a relatively small subset of genes—known as dosage-
sensitive genes (DSGs)—could be responsible for these
phenotypes. Alternatively, aneuploid phenotypes may
be the consequence of copy number changes of numerous
genes, which have little phenotypic impact when misex-
pressed on their own. For instance, in Down syndrome
(DS), caused by trisomy for human chromosome 21, the
contribution of DSGs to phenotypes is debated. The
“few critical genes” hypothesis predicts that a small num-
ber of triplicated genes causes the growth, developmental,
and cognitive abnormalities characteristic of the con-
dition. Indeed, previous studies mapped DS phenotypes
to a genomic region known as the DS critical region
(DSCR) (Rahmani et al. 1990; for review, see Rachidi
and Lopes 2007). DSCR1, located in this region, was
shown to protect individualswithDS fromdeveloping sol-
id tumors (Baek et al. 2009). Triplication of APP (amyloid
precursor protein) drives early-onset dementia in individ-
uals with DS (Rumble et al. 1989; Rovelet-Lecrux et al.
2006; Theuns et al. 2006).
While some characteristics of DS could be attributed to
changes in dosage of specific genes, other characteristics
of the condition could not (Olson et al. 2004a,b, 2007; Kor-
bel et al. 2009). In particular, phenotypes such as de-
creased proliferative capacity, a characteristic of not
only human trisomy 21 cells but all constitutive aneuploi-
dies (for review, see Torres et al. 2008), may be caused by
cumulative effects of genes for which individual copy
number alterations have minimal effects on fitness. A se-
ries of budding yeast strains harboring single additional
chromosomes (disomes) is an ideal system to investigate
which aspect of the aneuploid condition—individual
DSGs or cumulative effects ofmany genes—is responsible
for the decreased proliferative capacity in aneuploid cells
across species. Herewe show that changes in copy number
of the most DSGs on a chromosome are insufficient to
drive aneuploid proliferation defects. We conclude that
the proliferation defect of disomes is largely caused by
simultaneous copy number changes that are benign
independently.
Results and Discussion
A method to determine the contribution of DSGs
to the proliferation defect of disomic yeast
A previous genome-wide analysis shed light on which
yeast genes cause proliferation defectswhen present in ad-
ditional copies. The “genetic tug of war” (gTOW) method
was used to determine the copy number at which a gene
inhibits cell proliferation (Makanae et al. 2013). For
gTOW, the gene of interest and its regulatory elements
are present on a plasmid that can reach a high copy num-
ber to promote cell growth inmedium lacking leucine due
to the presence of a hypomorphic LEU2 allele (leu2-89)
(Fig. 1A; Moriya et al. 2012). However, toxicity of the
gene of interest prevents attaining high copy number
even in growth conditions that select for the presence of
the plasmid. Thus, plasmid copy number is a direct read-
out of maximal gene copy number tolerated by the cell
(Moriya et al. 2012). The majority of yeast genes exhibit
upper limits well over 75 copies (Makanae et al. 2013).
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However, 115 genes have an upper limit of≤10 copies, and
55 genes are not tolerated atmore than five copies per hap-
loid genome (Makanae et al. 2013). Other approaches in-
dependently demonstrated that 76% of these genes were
toxic upon overexpression (Boyer et al. 2004; Gelperin
et al. 2005; Sopko et al. 2006; Douglas et al. 2012; Maka-
nae et al. 2013), indicating that the genome-wide gTOW
screen successfully identified DSGs in the yeast genome.
Previously, we generated 13 of 16 possible budding
yeast disomies and found that all 13 disomies cause a
decrease in fitness (Torres et al. 2007). We chose nine of
the 13 disomic yeast strains (IV, V, VIII, IX, X, XI, XIV,
XV, and XVI) to test whether the genes with copy number
limits of five or fewer (henceforth DSGs[5]) (Table 1) could
be responsible for the proliferation defects exhibited by
these disomic yeast strains. We reasoned that genes that
inhibit cell proliferation at five copies could slow prolifer-
ation when present at two copies, as occurs when haploid
cells harbor an extra copy of a chromosome. We created
centromeric (CEN) plasmids containing DSGs along
with endogenous regulatory elements to mimic the single
extra gene copy in disomes (Supplemental Table 1) and
then examined the effects on cell proliferation in other-
wise wild-type haploid strains.
To ensure that the CEN plasmids recapitulate copy
number changes as they occur in cells harboring an extra
chromosome, we conducted a series of control experi-
ments. We first determined whether CEN plasmids them-
selves interfere with cell proliferation. Introducing three
CEN plasmids with no coding sequence other than
genes encoding selectable markers did not significantly
alter cell proliferation, as judged by doubling time mea-
surements (Supplemental Fig. 1). We then tested the con-
sequences of including coding sequences on these
plasmids. Cells bearing one or twoCENplasmids carrying
a total of three to six genes that should not significantly
slow doubling time did not interfere with proliferation.
However, cells bearing three CEN plasmids—each con-
taining multiple yeast genes, for a total of six to eight
genes not among the DSGs[5]—did slow proliferation in
haploid strains (Supplemental Fig. 1). The fact that intro-
duction of multiple CEN plasmids slows cell proliferation
(Futcher andCarbon 1986) could contribute to this pheno-
type. Based on these control experiments, we restricted
our analysis to no more than two CEN plasmids.
Next, we verified whether it was possible to detect pro-
liferation defects caused by a single additional copy of a
DSG. Consistent with previous studies (Liu et al. 1992),
we found that introduction of a CEN plasmid carrying
the actin-encoding gene ACT1 impaired cell proliferation
Figure 1. Effects of genes with copy number limits of five or fewer
(DSGs[5]) on cell proliferation. (A) The gTOW plasmid contains a
gene under the control of its endogenous regulatory elements, a mul-
ticopy 2-µm origin, and the hypomorphic leu2-89 allele (a LEU2 gene
with a truncated promoter) (Moriya et al. 2012). (B–I ) DSGs[5] on cen-
tromeric (CEN) plasmids were introduced into haploid wild-type
(WT) cells. Doubling times of cells grown at 25°C in YEPDwere deter-
mined by measuring OD600 every 15 min for 24 h. Genes were
grouped into graphs according to their chromosomal location. Dark-
gray bars represent control strains carrying empty plasmids, light-
gray bars represent the corresponding disomic strain (Dis), and striped
bars represent DSG plasmid-containing strains, with gene names list-
ed directly below. Empty vector CEN plasmid controls were EP1-
TRP1, EP2-HIS3, and EP3-LEU2. SD is shown. (B) (∗∗∗∗) P < 0.0001.
(G) (∗∗) P = 0.0014. (H) (∗∗∗∗) P < 0.0001; (I ) (∗∗∗∗) P < 0.0001, (∗∗) P =
0.008; Student’s t-test. The strains used, in order, were A2587 and
A36983 (B); A22361, A28266, A36950, and A36937 (C ); A22361,
A13975, A36950, and A36931 (D); A22361, A24367, A36950, and
A36926 (E); A22361, A28344, A36951, and A36941 (F ); A22361,
A28265, A36950, and A36927 (G); A22361, A34149, A36950,
A36944, A36951, A36945, A36952, and A36946 (H); and A22361,
A34149, A36953, A36947, A36954, A36948, A36955, and A36949 (I ).
Table 1. DSGs from the gTOW screen listed by chromosome
location and copy number upper limit (Makanae et al. 2013)
Five or fewer copies
Five to 10
copies 10–20 copies
I 0 MYO4 FUN30,
PMT2
II 0 APE3, OM14,
PET9, TEF2
KAP104,
SHE1,
UBC4
IV ARF1, SAC6 12 10
V GLN3 14 2
VIII SFB3, STE12 DMA1, MPC2,
MYO1, OPI1
2
IX PRK1 AXL2, TED1 2
X BFA1, IRC8, KAR2,
TPK1
HSP150 7
XI SPC42, TPK3 0 (1/2) SDS22
XIV KSH1, PUB1, SSN8 MKS1, POR1
TOM70
7
XV EFT1, SLG1 RPS12 6
XVI HAA1, KES1, PEP4,
TEF1, TPK2, VPS
(six of 10)
4 0
Genes analyzed in this study are listed by name, with the addi-
tional quantity of DSGs identified by gTOW indicated
numerically.
Dosage change of many genes drives slow doubling
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(Fig. 1B). We conclude that the addition of CEN plasmids
to haploid wild-type strains can be used to mimic gene
copy number changes as they occur in disomic strains.
Assessing the contribution of low-copy-limit DSGs
to the proliferation defects of aneuploid cells
All disomic yeast strains exhibit proliferation defects (Tor-
res et al. 2007), but onlyonedisomy, disomyVI, is lethal, as
this chromosome harbors the β-tubulin-encoding gene
TUB2 (Neff et al. 1983; Katz et al. 1990; Liu et al. 1992).
The reasonswhy disomes proliferatemore slowly than eu-
ploid cells under standard growth condition are unknown.
To determinewhether the slow proliferation of disomes is
caused by two copies of DSGs[5], we compared the dou-
bling times of yeast strains harboring a specific disomy
with wild-type strains containing CEN plasmids carrying
DSGs[5] encoded by the disomic chromosome. For in-
stance, chromosome XI encodes two DSGs[5]: SPC42 and
TPK3 (Table 1). Introduction of a CEN plasmid carrying
these two genes into wild-type cells did not significantly
lengthen cell cycle time (Fig. 1C) even though expression
of the two genes was comparable with that of disome XI
cells (Supplemental Fig. 2N). Similar resultswereobtained
for DSGs[5] encoded on chromosomes IX (PRK1) (Fig. 1D;
Supplemental Fig. 2J), VIII (SFB3 and STE12) (Fig. 2A; Sup-
plemental Fig. 2H), X (BFA1,KAR2, IRC8, and TPK1) (Fig.
2B; Supplemental Fig. 2L,M), andXV (EFT1 and SLG1) (Fig.
2C; Supplemental Fig. 2R). Introducing DSGs[5] encoded
onchromosomes IV (ARF1andSAC6) (Fig. 1E; Supplemen-
tal Fig. 2F) and XIV (KSH1, PUB1, and SSN8) (Fig. 1F; Sup-
plemental Fig. 2P) into wild-type cells did not slow
proliferation either; however, in these two cases, expres-
sion of one of the DSGs[5] (SAC6 or PUB1) (Supplemental
Fig. 2F,P) from the CEN plasmid did not reach expression
levels observed in the disomes.
Only three DSGs[5] led to a significant proliferation
defect when expressed from a CEN plasmid. GLN3, the
sole DSG[5] encoded on chromosome V, slowed the dou-
bling time of wild-type cells by 5.1 min (±1.3 min) (Fig.
1G; Supplemental Fig. 2G). For comparison, an additional
copy of chromosome V increases doubling time by 33min
(±3.1 min). DSGs[5] encoded on chromosome XVI also
slowed proliferation. Chromosome XVI encodes 10 DSGs
[5] (Table 1). Cells disomic for chromosomeXVI proliferate
25min (±2.3min) slower than wild type (Fig. 1H,I). We ex-
amined the effects of six chromosome XVI DSGs[5] indi-
vidually and in combination. A plasmid containing TEF1
and VPS4 slowed doubling time by 6.3 min (±0.7 min)
(Fig. 1H; Supplemental Fig. 2U). Additionally, when com-
bined with a plasmid harboring the DSGs[5] KES1 and
PEP4, time of doubling increased by 14.6 min (±1.8 min)
compared with empty vector controls (Fig. 1I). The addi-
tion of HAA1 and TPK2 with TEF1 and VPS4 did not
slowproliferationmore thanTEF1 andVPS4 alone (Fig. 1I).
To determine how an additional copy of KES1, PEP4,
TEF1, and VPS4 interferes with cell proliferation, we ana-
lyzed progression through the cell cycle in cultures syn-
chronized by centrifugal elutriation. Previous cell cycle
studies of disome XVI cells revealed a substantial G1 de-
lay, largely due to a growth defect (Thorburn et al. 2013)
and ametaphase delay (Torres et al. 2007). Wild-type cells
expressing an extra copy of KES1, PEP4, TEF1, and VPS4
exhibited a minor G1 delay, as judged by a subtle delay
in bud formation (Supplemental Fig. 3A) and a 15-min-
long metaphase delay (Supplemental Fig. 3B). TEF1 over-
expression was previously proposed to interfere with
bud formation, which could explain the slight delay in
bud emergence (Munshi et al. 2001). We do not yet under-
stand why expressing this gene combination causes a
metaphase delay. Overall, however, we conclude that
DSGs present in low copy number cannot account for
the proliferation defect observed in disomic yeast strains.
Ten-copy-limit DSGs cause a minor cell
proliferation defect
Next, we investigated the possibility that synergistic ef-
fects of genes with slightly higher copy number limits ac-
count for the proliferation defects of disomes. We
examined the consequences of expressing genes with
copy number limits of <10 (limit 0–10, henceforth DSGs
[10]) from CEN plasmids. Chromosome VIII encodes six
DSGs[10] (Table 1). Expression of five of these genes
(DMA1, MYO1, OPI1, SFB3, and STE12) together did
not interferewith cell proliferation (Fig. 2A; Supplemental
Fig. 2H,I). Similar results were obtained for DSGs[10] en-
coded on chromosomes X (BFA1, KAR2, HSP150, IRC8,
and TPK1) (Fig. 2B; Supplemental Fig. 2L,M), XV (EFT1,
Figure 2. Consequences of an additional copy of genes with copy
number limits of <10 (limit 0–10, henceforth DSGs[10]) on cell prolif-
eration. (A–F ) Cells were grown as described in Figure 1. Genes were
grouped into graphs according to chromosomal location. Dark-gray
bars represent control strains carrying empty plasmids, light-gray
bars represent the corresponding disomic strain (Dis), and striped
bars represent DSG plasmid-containing strains. Empty vector CEN
plasmid controls were EP1-TRP1, EP2-HIS3, and EP3-LEU2. SD is
shown. (E) (∗∗) P = 0.001. (F ) (∗∗∗) P = 0.0002; Student’s t-test. The
strains, in order, were A22361, A27036, A35953, and A36930 (A);
A22361, A27093, A36953, and A36936 (B); A22361, A29730,
A36950, and A36943 (C ); A22361, A13975, A36954, and A36933
(D); A22361, A12685, A36950, and A36923 (E); and A22361,
A28344, A36953, and A36942 (F ).
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RPS12, and SLG1) (Fig. 2C; Supplemental Fig. 2R), and IX
(AXL2, PRK1, and TED1) (Fig. 2D; Supplemental Fig. 2J,
K). Coexpression of DSGs[10] from either chromosome
II or XIV conferred a measurable proliferation defect.
APE3,OM14, PET9, and TEF2 expressed from aCEN plas-
mid lengthened doubling time by 5.8 min (±1.4 min)
compared with control cells (Fig. 2E; Supplemental Fig.
2D). Cells with plasmids containing the six genes with
limits from 0 to 10 on chromosome XIV exhibited dou-
bling times 15 min (±3.2 min) slower than control cells
(KSH1, MKS1, POR1, PUB1, SSN8, and TOM70) (Fig. 2F;
Supplemental Fig. 2P,Q). For comparison, the doubling
time of disome XIV cells is 32 min (±5.2 min) slower
than that of wild-type cells (Fig. 2F).
Furthermore, for chromosomes I, II, and XI, we deter-
mined the effects of expressing all genes with upper limits
of≤20 copies (DSGs[20]; for chromosomeXI, wewere only
able to analyze three of four DSGs[20]). Proliferation was
not significantly slowed when DSGs[20] encoded on chro-
mosome I or XI were expressed from CEN plasmids (Fig.
3A,B; Supplemental Fig. 2B,C,N,O). Coexpression of all
DSGs[20] located on chromosome II led to an increase in
doubling time by 6.6 min (±1.4 min) (Fig. 3C; Supplemen-
tal Fig. 2D,E) compared with cells containing empty vec-
tors, which is a slightly slower rate of doubling than
seen in cells harboring a plasmid containing chromosome
II DSGs[10] alone (Fig. 2E).
Additionally, we note that an extra copy of DSGs did
not cause other phenotypes characteristic of disomic
yeast strains such as sensitivity to high temperature, cy-
cloheximide, or phleomycin (Supplemental Fig. 4). This
was not unexpected given that gTOW DSGs were identi-
fied based on their proliferation defect, not sensitivity to
adverse growth conditions.
Our results indicate that a doubling in gene dosage of
DSGs[5] is partly responsible for the proliferation defect
of only two out of nine disomic yeast strains analyzed
(disomes V and XVI). A portion of the proliferation defect
of an additional two disomies (disomes II and XIV) can
be explained by a doubling in gene dosage of DSGs[10].
Nevertheless, it is important to state that no plasmids
containing DSGs slowed doubling times to rates seen in
cells expressing an extra copy of the corresponding whole
chromosome. These results support the conclusion
that the proliferation defect observed in disomic yeast
strains is caused by increased expression of genes that,
altered individually, have little or no observable effect
rather than a few proliferation antagonists at altered
copy number. We suspect that this concept applies to
other phenotypes widespread among aneuploid cells.
For instance, in other work, we were not able to identify
a single gene responsible for the hydroxyurea sensitivity
of disome VIII strains (Blank et al. 2015). Additionally,
Chen et al. (2015) were unable to ascribe the hygromy-
cin sensitivity of disome XV cells to a specific gene
combination.
Deletion of DSGs from disomic strains does not
improve cellular fitness
Our results reveal that an additional copy of someDSGs is
sufficient to explain a small portion of the proliferation de-
lay in disomic cells, but are DSGs necessary for the prolif-
eration defects of disomic yeast strains? To address this
question, we investigated the consequences of deleting
one copy of GLN3 in cells disomic for chromosome
V. Introduction of an extra copy of GLN3 into wild-type
cells subtly impaired proliferation (Fig. 1G). However, dis-
ome V cells lacking one copy of GLN3 did not proliferate
faster than cells disomic for a wild-type copy of chromo-
some V (Fig. 4A). Similar results were obtained for TEF1
and VPS4. Expression of these DSGs slows proliferation
(Fig. 1H), but deleting one copy in disome XVI cells did
not improve proliferation (Fig. 4B). Deletion of one copy
of other chromosome XVI DSGs[5] (TPK2 or KES1) did
not improve proliferation rate either (Fig. 4B).
Similarly, we asked whether low-copy-limit genes
might be necessary for disomic proliferative defects even
if they were not sufficient. We deleted one copy of the
DSG[5] PRK1, the DSGs[10] TED1 and AXL2, and the
DSG[20] GVP36 in disome IX cells. Doubling time mea-
surements did not reveal either a decrease in cell cycle
duration or a fitness advantage when competed against
the parental disome IX strain (Fig. 4C). The parental and
DSG deletion disomic strains maintained an approxi-
mately equal share of the population following serial dilu-
tions for 48 h. Similar results were obtained for DSGs
encoded by chromosome XI (Fig. 4D). These data demon-
strate that individual geneswhose alteration in copy num-
ber is most toxic are not solely responsible for the
proliferation defect of cells harboring an additional copy
of the entire chromosome.
Concluding remarks
In summary, our data indicate that DSGs with low copy
number limits can interfere with cell proliferation when
present in two copies in haploid strains, but their effects
cannot explain the significant proliferation defect seen
in cells harboring an additional copy of the entire chromo-
some on which they are located. We surveyed 11 chromo-
somes for effects of an extra copy of low-copy-limit DSGs
on proliferation, and none revealed substantial growth al-
teration. Thus, our study conclusively excludes the “few
critical genes” hypothesis as a possible explanation for
the growth defect of disomic yeast strains and implies
Figure 3. Effects of DSGs[20] on cell proliferation. (A–C ) Cells were
grown as described in Figure 1. Genes were grouped into graphs ac-
cording to their chromosomal location. Dark-gray bars represent con-
trol strains carrying empty plasmids, light-gray bars represent the
corresponding disomic strain (Dis), and striped bars represent DSG
plasmid-containing strains. Empty vector CEN plasmid controls
were EP1-TRP1, EP2-HIS3, and EP3-LEU2. SD is shown. (∗∗∗∗) P <
0.0001; Student’s t-test. The strains used, in order, were A22361,
A12683, A36954, and A36922 (A); A22361, A28266, A36953, and
A36939 (B); and A22361, A12685, A35954, and A36925 (C ).
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that this aneuploidy-associated phenotype is caused by an
increase in dosage of a large number of genes not harmful
when amplified individually. To our knowledge, this is
the first systematic analysis to demonstrate that subtle
changes in gene dosage have significant phenotypic conse-
quences when they occur at a chromosome-wide scale.
This conclusion may not only apply to the proliferation
defect of aneuploid yeast strains. Previous studies of seg-
mental aneuploidies in Drosophila melanogaster showed
that larger deletions and duplications were more deleteri-
ous than smaller ones (Lindsley et al. 1972).
Our findings may also have implications for under-
standing the origins of phenotypes of chromosome gains
and losses in humans. Phenotypes observed in monoso-
mies are likely due to a combination of specific gene
copy number alterations and mass effects of individually
harmless genes, as 1.5%–5% of the human genome is pre-
dicted to be haploinsufficient (Dang et al. 2008; Huang
et al. 2010). However, contribution ofmass action of genes
with little or no phenotypic effect when varied individual-
ly could significantly impact phenotypes associated with
trisomy. For example, despite intense efforts, no specific
gene or chromosomal region has been identified as respon-
sible for the general growth retardation, developmental
abnormalities, and cognitive deficiencies characteristic
of DS. In developing a framework to think about treating
diseases involving whole-chromosome or segmental
aneuploidies, our data suggest that, rather than solely
searching for therapies that target single genes, we also
need to identify methods to increase the overall fitness
of aneuploid cells.
Materials and methods
Yeast strains and plasmids
Plasmids used in this study are listed in Supplemental Table S1. Plasmids
were created via cloning as described in Gibson et al. (2009) or were from
the MoBY ORF collection (Ho et al. 2009). Representative plasmids were
sequenced to ensure that no alterations in sequence arose during cloning.
Strains used in this study are listed in Supplemental Table S2. All strains
are derivatives of W303. Disomic strain generation is described in Torres
et al. (2007). Karyotypes of all aneuploid strains were confirmed by com-
parative genomic hybridization (CGH) as performed in Torres et al.
(2007) and analyzed with Java TreeView.
Doubling time analysis
Strains were grown overnight at room temperature in medium to select
for maintenance of plasmids. The following morning strains were diluted
to OD600 = 0.1 in yeast extract/peptone medium containing 2% glucose
(YEPD). The growth rate was measured in triplicate using a Biotek plate
reader at 25°C. OD600 measurements were taken every 15 min for 24
h. Only the period of exponential growth was used to determine doubling
time. Two to four transformants per plasmid were tested on at least two
different days and compared with a wild-type strain carrying the relevant
empty vector plasmid. Data were accumulated using Gen5 software. Sta-
tistics were performed using GraphPad Prism software.
Competition experiments
Approximately equal amounts of cells with and without integrated PGK1-
GFP were mixed in selective medium (−His +G418) at OD600 = 0.15 and
maintained in exponential growth phase at room temperature. Samples
were taken every 12 h for 48 h. Each sample was fixed for 5 min in 3.7%
formaldehyde in KPi (pH = 6.4). Relative cell populations in the cultures
were measured by quantifying the percentage of GFP-positive versus
GFP-negative cells via flow cytometry.
Real-time RT–PCR
Analysis of gene expression was performed as previously described (Thor-
burn et al. 2013).
Elutriation
Elutriation performed as described in Thorburn et al. (2013) with the ex-
ception that elutriated cells were resuspended in YEPD at 25°C.
Figure 4. Deletion of one copy of DSGs from disomic yeast strains
does not improve cellular fitness. (A) Cells harboring an additional
copy of chromosome V (A28265) or an additional copy of chromo-
some V lacking GLN3 (A36470) were grown as described in Figure 1
to measure their doubling time. (B) Cells harboring an additional
copy of chromosome XVI (A34149) or an additional copy of chromo-
some XVI lacking the indicated genes (A36585, A36650, A36689,
and A36859) were grown as described in Figure 1 to measure their
doubling time. (C, left graph) Cellswith an additional copy of chromo-
some IX (A13975) or an additional copy of chromosome IX lacking the
indicated genes (A36233, A36215, and A36069) were grown as de-
scribed in Figure 1 to measure their doubling time. The middle and
right graphs show competition experiments in which equal numbers
of disome IX cells harboringGFP (A36219) and disome IX cells lacking
the indicated genes (A36233 and A36215) were coinoculated in –His
G418 medium. The percentages of GFP-positive and GFP-negative
cells were monitored at the indicated times. (D, left graph) Cells
with an additional copy of chromosome XI (A28266) or an additional
copy of chromosome XI lacking the indicated genes (A36919 and
A36336) were grown as described in Figure 1 to measure their dou-
bling time. The middle and right graphs show competition experi-
ments in which equal numbers of disome XI cells expressing GFP
(A36222) and GFP− disome XI cells lacking the indicated genes
(A36919 and A36336) were coinoculated in −His G418 medium.
The percentages of GFP-positive and GFP-negative cells were moni-
tored at the indicated times.
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Indirect in situ immunofluorescence
Indirect in situ immunofluorescence of α-tubulin was performed as de-
scribed previously (Kilmartin and Adams 1984). Cells were imaged with
a Zeiss Axioplan 2 microscope (Zeiss).
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